Skip to main content
SpringerLink
Log in

Multimodal Management of Metastatic Disease

  • Chapter
Current Treatment of Retroperitoneal Sarcomas

Part of the book series: Updates in Surgery ((UPDATESSURG))

  • 563 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Blay J-Y, van Glabbeke M, Verweij J et al (2003) Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39(1):64–69

    Article  Google Scholar 

  2. Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG) (2018) Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol 29(4):857–871

    Article  Google Scholar 

  3. Messiou C, Moskovic E, Vanel D et al (2017) Primary retroperitoneal soft tissue sarcoma: imaging appearances, pitfalls and diagnostic algorithm. Eur J Surg Oncol 43(7):1191–1198

    Article  CAS  Google Scholar 

  4. Abdalla EK, Pisters PW (2002) Metastasectomy for limited metastases from soft tissue sarcoma. Curr Treat Options Oncol 3(6):497–505

    Article  Google Scholar 

  5. Navarria P, Ascolese AM, Cozzi L et al (2015) Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer 51(5):668–674

    Article  Google Scholar 

  6. Jones RL, McCall J, Adam A et al (2010) Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol 36(5):477–482

    Article  CAS  Google Scholar 

  7. Anaya DA, Lahat G, Liu J et al (2009) Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg 249(1):137–142

    Article  Google Scholar 

  8. Judson I, Verweij J, Gelderblom H et al; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2014) Doxorubicin alone versus intensified doxorubicin plus ifosfamide for front-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 15(4):415–423

    CAS  PubMed  Google Scholar 

  9. Bramwell V, Anderson D, Charette M; Sarcoma Disease Site Group (2003) Doxorubicinbased chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev (3):CD003293

    Google Scholar 

  10. Falk AT, Moureau-Zabotto L, Ouali M et al; Groupe Sarcome Français-Groupe d’Etude des Tumeurs Osseuses (2015) Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. Clin Oncol (R Coll Radiol) 27(1):48–55

    CAS  Google Scholar 

  11. Italiano A, Toulmonde M, Cioffi A (2012) Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol 23(6):1601–1607

    Article  CAS  Google Scholar 

  12. Jones RL, Fisher C, Al-Muderis O, Judson IR (2005) Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 41(18):2583–2860

    Article  Google Scholar 

  13. Sanfilippo R, Bertulli R, Marrari A et al (2014) High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. Clin Sarcoma Res 4(1):16

    Article  Google Scholar 

  14. Patel SR, Vadhan-Raj S, Papadopolous N et al (1997) High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies — dose-response and schedule dependence. J Clin Oncol 15(6):2378–2384

    Article  CAS  Google Scholar 

  15. Demetri GD, von Mehren M, Jones RL et al (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34(8):786–793

    Article  CAS  Google Scholar 

  16. Le Cesne A, Blay J-Y, Domont J et al (2015) Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol 16(3):312–319

    Article  Google Scholar 

  17. Schöffski P, Chawla S, Maki RG et al (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387(10028):1629–1637

    Article  Google Scholar 

  18. Gottlieb JA, Benjamin RS, Baker LH et al (1976) Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 60(2):199–203

    CAS  PubMed  Google Scholar 

  19. Sleijfer S, Ouali M, van Glabbeke M et al (2010) Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer Soft-Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 46(1):72–83

    Article  CAS  Google Scholar 

  20. Casali PG, Abecassis N, Bauer S et al (2018) Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Epub ahead of print] doi:10.1093/annonc/mdy096

    Google Scholar 

  21. Gottlieb JA, Baker LH, Quagliana JM et al (1972) Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 30(6):1632–1638

    Article  CAS  Google Scholar 

  22. Antman K, Crowley J, Balcerzak SP et al (1993) An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11(7):1276–1285

    Article  CAS  Google Scholar 

  23. Maki RG, Wathen JK, Patel SR et al (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration study 002 [corrected]. J Clin Oncol 25(19):2755–2763

    Article  CAS  Google Scholar 

  24. Hensley ML, Maki R, Venkatraman E et al (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20(12):2824–2831

    Article  CAS  Google Scholar 

  25. Pautier P, Floquet A, Penel N et al (2012) Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 17(9):1213–1220

    Article  CAS  Google Scholar 

  26. Seddon B, Strauss SJ, Whelan J et al (2017) Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcoma (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 18(10):1397–1410

    Article  CAS  Google Scholar 

  27. van der Graaf WT, Blay JY, Chawla SP et al; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829):1879–1886

    Google Scholar 

  28. Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241(5):776–783; discussion 783–785

    Article  Google Scholar 

  29. Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235(6):759–766

    Article  Google Scholar 

  30. Schwartz SI (1995) Hepatic resection for noncolorectal nonneuroendocrine metastases. World J Surg 19(1):72–75

    Article  CAS  Google Scholar 

  31. Mudan SS, Conlon KC, Woodruff JM et al (2000) Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 88(1):66–74

    Article  CAS  Google Scholar 

  32. Takemura N, Saiura A (2017) Role of surgical resection for non-colorectal non-neuroendocrine liver metastases. World J Hepatol 9(5):242–251

    Article  Google Scholar 

  33. Lang H, Nussbaum KT, Kaudel P et al (2000) Hepatic metastases from leiomyosarcoma: a single-center experience with 34 liver resections during a 15-year period. Ann Surg 231(4):500–505

    Article  CAS  Google Scholar 

  34. DeMatteo RP, Shah A, Fong Y et al (2001) Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 234(4):540–547

    Article  CAS  Google Scholar 

  35. Pawlik TM, Vauthey JN, Abdalla EK et al (2006) Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 141(6):537–543; discussion 543–544

    Article  Google Scholar 

  36. Marudanayagam R, Sandhu B, Perera MT et al (2011) Liver resection for metastatic soft tissue sarcoma: an analysis of prognostic factors. Eur J Surg Oncol 37(1):87–92

    Article  CAS  Google Scholar 

  37. Choong PF, Pritchard DJ, Rock MG et al (1995) Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients. Acta Orthop Scand 66(6):561–568

    Article  CAS  Google Scholar 

  38. Pastorino U, Buyse M, Friedel G et al; International Registry of Lung Metastases (1997) Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 113(1):37–49

    CAS  PubMed  Google Scholar 

  39. Billingsley KG, Burt ME, Jara E et al (1999) Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg 229(5):602–610; discussion 610–612

    Article  CAS  Google Scholar 

  40. Roth JA, Putnam JB Jr, Wesley MN, Rosenberg SA (1985) Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Cancer 55(6):1361–1366

    Article  CAS  Google Scholar 

  41. Casson AG, Putnam JB, Natarajan G et al (1992) Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer 69(3):662–668

    Article  CAS  Google Scholar 

  42. Kim S, Ott HC, Wright CD et al (2011) Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes. Ann Thorac Surg 92(5):1780–1786; discussion 1786–1787

    Article  Google Scholar 

  43. Putnam JB Jr, Roth JA, Wesley MN et al (1984) Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft-tissue sarcoma. J Thorac Cardiovasc Surg 87(2):260–268

    PubMed  Google Scholar 

  44. Kon Z, Martin L (2011) Resection for thoracic metastases from sarcoma. Oncology (Williston Park) 25(12):1198–1204

    Google Scholar 

  45. García Franco CE, Torre W, Tamura A et al (2010) Long-term results after resection for bone sarcoma pulmonary metastases. Eur J Cardiothoracic Surg 37(5):1205–1208

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center Rozzano, Milan, Italy

    Alexia F. Bertuzzi

Authors
  1. Alexia F. Bertuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Umberto Cariboni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matteo M. Cimino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guido Torzilli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexia F. Bertuzzi .

Editor information

Editors and Affiliations

  1. Surgical Oncology Unit, Department of Surgery, Humanitas Clinical and Research Center, Rozzano, Milan, Italy

    Vittorio Quagliuolo

  2. Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

    Alessandro Gronchi

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag Italia

About this chapter

Cite this chapter

Bertuzzi, A.F., Cariboni, U., Cimino, M.M., Torzilli, G. (2019). Multimodal Management of Metastatic Disease. In: Quagliuolo, V., Gronchi, A. (eds) Current Treatment of Retroperitoneal Sarcomas. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-3980-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-3980-3_13

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-3979-7

  • Online ISBN: 978-88-470-3980-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation